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Melanoma incidence rates in Norway have increased 8-fold in the last decades, resulting 
in the highest mortality rates in Europe. Malignant melanoma is an extremely aggressive skin 
cancer and has the highest propensity of all cancers to metastasize to the brain. Melanoma 
patients with brain metastases have a very poor prognosis, and even with medical treatment the 
average survival time after diagnosis is around 4 months.  The presence of the blood brain 
barrier limits around 98% of chemotherapeutic drugs from entering the brain and targeted 
therapies often lead to development of acquired resistance after a few months.  
Melanoma has the highest mutation rates of all malignant tumours, often resulting in 
the dysregulation of the MAPK and PI3K signaling pathways, that promote survival and 
proliferation of tumour cells. PI3K is a phosphatidylinositol 3-kinase that initiates the 
downstream signaling in response to a receptor tyrosine kinase activation and is currently being 
targeted to inhibit tumour growth. It has four major isoforms, with PI3Kα being the most active 
in melanoma. HS-173 is an extremely potent PI3Kα inhibitor that has been shown to inhibit 
tumour growth in several cancers at low doses, regardless of mutational status. The main aim 
of this thesis was to evaluate the effect of an isoform-specific PI3Kα inhibitor on four human 
brain metastatic melanoma cell lines in vitro. 
HS-173 showed a dose-dependent inhibition of cell viability for all four cell lines in 
monolayer cultures, all with IC50 doses below 1 µM. Microscopy revealed that HS-173 induced 
a rounded morphological change after treatment. HS-173 also reduced migration and 
proliferation in all the cell lines as shown by a wound healing assay. Through flow cytometric 
analysis, we found that apoptosis was induced by the drug. Western blotting revealed that HS-
173-induced inhibition of PI3Kα downregulated the activation of downstream effectors, in 
particular the phosphorylation of Akt in all four cell lines. Also, some inhibition of mTOR and 
PI3Kα expression levels was seen.  
In conclusion, we found that HS-173 is an effective inhibitor of melanoma brain 
metastases in vitro, through inhibition of cell growth, migration and viability, induction of 






1.1 What is Skin Cancer?  
Skin cancer is one of the most widespread malignancies in the world and is commonly 
separated into two categories: non-melanoma skin cancers (NMSC) and malignant melanoma.  
NMSCs comprise 99% of all skin cancers, with the majority of cases consisting of basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC)1. While BCC and SCC make up the 
majority of all skin cancer incidences, with rates 18-20 times higher than that of melanoma, the 
actual statistics for these cancers are quite unreliable as NMSCs are not necessarily reported to 
national cancer registries2. Both cancers have low mortality rates so vigilant reporting is 
uncommon, with metastases found in up to 0.05% of cases of BCC and 1.2% of cases of SCC2,3. 
BCC affects the basal cells of the epidermis, and SCC is found in squamous cells (Fig. 1.1)4. 
 
 
The final 1% of skin cancer incidence is attributed to melanoma, a cancer of the 
melanocytes in the epidermal layer of the skin. Melanocytes, found in the stratum corneum 
layer of the epidermis, alongside the basal cells, contain melanin that helps to protect the body 
from UV radiation-induced damage. Although melanoma cases make up less than 1% of all 
skin cancer cases, they account for the majority of skin cancer deaths (75%), and almost 1% of 
total cancer-related deaths5. 
1.1.1 Epidemiology, Incidence, and Survival 
Melanoma is the 19th most common cancer diagnosed in both women and men, with 
Norway having the 3rd highest incidence rate in the world and the highest in Europe, with 29.6 
Figure 1.1: Composition of normal layers of the skin: Illustration depicting the upper layers of the skin 
including major cells and locations within the tissue layers. Figure from The National Cancer Institute. Image 





cases per 100 000 people6. Since 1952, the incidence rate has increased eightfold across 
Norway7. According to the WHO Globocan 2018 world statistics of cancer, melanoma of the 
skin is the 5th most common form of cancer in Norway, and the 7th leading cause of cancer-
related deaths6. Women have a slightly higher rate of incidence than men, at 30.7 per 100 000 
compared to 29.0 per 100 000 respectively6. However, there is some evidence that over the age 
of 70, incidence in men is higher than in women. It has been speculated that the rates of 
melanoma are linked to socioeconomic status, as people with higher living standards can afford 
to go on vacation to sunny places or tan in solariums. Additionally, due to the lack of sun in 
Norway, it has been suggested that Norwegians tend to have more unhealthy tanning habits 
when there is sun available8,9. 
Men are more likely to be diagnosed on their trunk and back, while women have more 
cases on their lower extremities including legs and feet10. White non-Hispanic populations are 
the most at risk of all races11 and the geography of incidence reflects the racial stratification of 
melanoma. The highest rates are found in countries with large non-Hispanic Caucasian 
populations exposed to high UV such as New Zealand and Australia (35.8 and 35.1 per 100 000 
respectively)12.   
Survival rates for melanoma vary widely, primarily according to the race of the patient 
and staging of the disease. Mortality rates have been gradually increasing over the last several 
decades in areas with high incidences, such as Australia, New Zealand, as well as Norway and 
Sweden. Interestingly, in the United States the 5-year survival rate (normalized to all stages) 
remains at around 94% for non-Hispanic Whites, however African American rates are much 
lower at around 64%5. This variation has been attributed to socioeconomic reasons, as those 
with higher status have more medical access, insurance and education to aid in early 
diagnosis11,13. In 2012, the cutaneous melanoma mortality rate in Norway was also the highest 
in Europe and third in the world. On average, Norwegians have a more advanced staged 
melanoma at diagnosis, possibly due to a lack of awareness, which increases the risk of 
mortality14. It is important to note that these survival rates are overall averages, although the 
melanoma survival rate varies widely between stages and grades. This will be further described 
in Section 1.5.  
1.2 Causes and Risk Factors of Melanoma 
Melanoma is considered a multifactorial cancer, due to the variety of risk factors that 





factors. Exogenous risk factors are external or environmental factors that are often mediated 
through lifestyle such as sun exposure. Endogenous risk factors are less modifiable and related 
to the inherent characteristics of a patient, such as DNA repair mechanisms or race15.  
The major environmental risk factor for melanoma, as well for the other skin cancers, 
is ultraviolet radiation (UVR) exposure. UVR has two wavelengths relevant for skin cancer, 
UVA and UVB. UVA can induce degenerative tissue damage deep in the skin, while UVB is 
the primary cause of sunburns and directly damages DNA through the formation of pyrimidine 
dimers16. Although there is some variance between cumulative and chronic sun exposure, there 
may be a correlation between melanoma and unaccustomed sun exposure, i.e. pale-skinned 
people and acute sunburns, which may explain why the rates are so high in countries with pale-
skinned populations and less sun (i.e. Norway and Sweden)17. Interestingly, chronic UV 
exposure is more correlated with non-melanoma skin cancers, although the reason behind this 
is not entirely understood18. A meta-analysis of UV light exposure and skin cancer found that 
the use of tanning beds before the age of 35 and childhood sunburns increase the risk of 
melanoma later in life, and that the highest risk group in Norway was women who used tanning 
equipment at least once a month between the ages of 20 and 2919. It has also been suggested 
that psoralen and ultraviolet A (PUVA), a treatment for psoriasis, has a dose-dependent increase 
in risk of melanoma in patients with pale, burn-susceptible skin20. Additionally, geographic 
location can also increase the risk, as the strength of UV rays along the equator is much stronger 
than in Northern Europe, giving some explaining to why melanoma rates are some of the highest 
in Australia and New Zealand6. It is speculated that ozone layer holes are allowing more UVB 
into our environment, and although there are no recent articles suggesting a causal effect, there 
are many studies predicting increased risk as ozone depletion worsens21-23.  
Other less common environmental factors include some photosensitive drugs that upon 
UVR exposure can lead to radical oxygen species (ROS) formation, and some cosmetic 
ingredients such as para-aminophenol and para-phenylenediamine which have carcinogenic 
properties when exposed to skin24.  
One endogenous risk factor of melanoma is race, as skin type is often denoted by 
genetics within races. The risk of developing malignant melanoma is 1 in 40 for non-Hispanic 
Caucasians, 1 in 1000 for Blacks and 1 in 200 for Latin Americans25. Different skin types within 
Caucasians also affect the individual risk, with type 1 and 2 having the highest risk when 





with higher melanoma risk as the UV-derived DNA damage from sunburns directly increases 
the chance of malignant tumour formation25.  
 
Another endogenous risk factor of melanoma is melanocytic naevi, colloquially known 
as moles. A meta-analysis found that the risk factor for people with 101-120 naevi was seven 
times higher than for those with less than 15 naevi, and people with at least 5 atypical naevi had 
five times higher incidence of melanoma than those with less than 5 naevi26. Atypical is defined 
as three of the following: poorly defined border, >5mm, varying colours, redness, and 
asymmetrical27. It was also found that up to ¾ of melanoma patients had previously reported 
their naevi to their doctor and in 25-50% of those it was shown that their tumour was associated 
with a naevi. Finally, naevi can also be formed through exposure to sunlight and the number 
alone can be an indication of UV exposure26. 
It has been indicated that melanoma can be familial. Inherited melanoma is typically 
found in patients under 40 years, usually with multiple cases within one side of the family28.  It 
is thought to be linked to a mutation in a gene important in the cell cycle pathway: cyclin-
dependent kinase inhibitor 2A (CDKN2A). CDKN2A encodes p16 and p14ARF which are 
negative regulators of cell proliferation, and have inactivating mutations in up to 40% of 
melanoma-prone families (3 or more cases of melanoma), but only in 8-15% of overall 
cases29,30. 
1.3 Biological Aspects of Melanoma 
Melanoma is a malignant neoplasm from melanocytes. Melanocytes are neural crest-
derived cells, the majority of which are found in the epidermis including skin and eye, but they 
can also found in other locations such as the nasal cavity and inner ear31. The majority of 
melanomas are found on the skin, and the most common forms of melanoma are cutaneous 
melanomas, which are comprised of the following sub-groups from most to least common: 
superficial spreading, nodular, lentigo maligna, and acral lentiginous18.  Melanoma can be 
derived from the meninges in the eyes and various mucosal tissues, with rarer forms arising in 
these areas which include mucosal lentiginous, intraocular, or desmoplastic melanoma5,18,32. 
Figure 1.2. Fitzpatrick Sun-Exposed Skin Types: Type I: always reddens, rarely tans. Type II: often 
reddens and rarely tans. Type III: sometimes reddens and gradually tans. Type IV and V: rarely redden 





Primarily, melanocytes are found in the epidermal-dermal junction and produce 
melanin, a pigmented biopolymer that darkens the skin and protects it from UVR. Skin colour 
is determined by the amount and distribution of melanocytes within the skin33. There are two 
forms of mammalian melanin, brown-black eumelanin and yellow-red pheomelanin31. 
Melanocytes produce melanin through a lysosome-like structure called a melanosome which is 
then shuttled to keratinocytes to protect the cells from UVR damage. Melanin functions as a 
UV-shielding molecule (specifically eumelanin) by scattering UVB photons to prevent the 
penetration of UV into the epidermis34. It has been estimated that melanin absorbs around 50-
75% of UVR. Melanin can also act as a free radical mediator to help minimize damage through 
ROS35. 
1.4 Molecular Aspects of Melanoma 
Melanoma is genetically heterogeneous, primarily because the main risk factor (UV 
radiation) can cause random mutations in the genome. It was recently found through whole-
genome sequencing that melanoma is the most highly mutated tumour out of all cancers studied 
(Fig. 1.3)36.   
A driver mutation is a mutation within a cell which gives a selected advantage in its 
microenvironment, such as increased survival or proliferative capacity.  These may be either 
within a tumour suppressor gene or a proto-oncogene. A tumour suppressor gene is a gene that 
regulates cell division and replication, and when the tumour suppression gene (such as 
CDK2NA) is mutated, it results in loss or reduction of its function, leading to uncontrolled cell 
growth. A proto-oncogene is a normal gene that contributes to cell growth, and when mutated 
(then called an oncogene) leads to overstimulation of the growth or survival pathways. These 
driver mutations promote genetic instability, which results in additional mutations, perpetuating 






The two most important signaling pathways found to be affected by mutations are the 
mitogen-activated protein kinase (MAPK) pathway and the phospho-inositide-3 (PI3K) 
pathway37, which both are involved in cell growth, survival, and proliferation. 
In melanoma, mutations in the BRAF gene in the MAPK pathway are the most prevalent, 
and are present in approximately 50% of cases38-40. The RAF family of proteins is comprised 
of signal transduction protein kinases, activated by the RAS family of G-proteins, that play a 
major role in the MAPK/ERK pathway to help mediate the cell response to growth factor 
signaling41,42. BRAF is highly regulated, efficiently activated by RAS and has a higher basal 
activity than the other RAFs such as CRAF and ARAF42,43.  BRAF is mutated in several other 
cancers in addition to melanoma, including cancers in the lung, breast, and liver44. In melanoma, 
97% of BRAF mutations are found in codon 600 of the gene, which corresponds to the active 
phosphorylation site of the protein. Of these 97%, 90% are comprised of a valine (V) to 
glutamic acid (E) (V600E) substitution45.  This mutation constituently activates the protein and 
induces resistance to feedback mechanisms, leading to increased cell proliferation46. It is also 
worth noting that BRAF-mutated tumours seem to have an increased propensity to metastasize 
to the brain47,48. 
The second most prevalent mutation in melanoma is found in the NRAS gene, also in 
the MAPK pathway. RAS proteins belong to a family of small GTPases that transduce growth 
signals through the binding of GTP and subsequent activation of downstream effectors, such as 
RAF. RAS gene mutations are the most commonly found alterations in all human cancers, in 
around 30% of all tumours49. In melanoma, activating NRAS mutations have been discovered 
Figure 1.3: Somatic mutation frequencies observed across several types of cancer. Each dot corresponds 
to a tumour compared to a normal tissue sample, with the vertical position representing totally frequency 
of somatic mutations in that tumour. Ordered by median mutation frequency from lowest (left) to highest 





in 15-30% of cases38,40,50. There are three codon ‘hotspots’ in which 98% of the mutations exist 
across all RAS isoforms: Q61, G12, and G1351. These mutations all increase the GTPase activity 
by favouring the GTP-bound active RAS protein52,53, and 20-fold more tumours harbour the 
Q61 arginine (Q61R) mutation, compared to G12 or G1354,55. BRAF and NRAS mutations have 
been found together, however the mutations are generally mutually exclusive50,56.  
Inactivating mutations in the tumour suppressor gene Neurofibromin 1 (NF1) have been 
discovered in approximately 15% of all cutaneous melanomas40, and are present in 50% of 
BRAF/NRAS wild-type tumours57,58. NF1 is a negative regulator of the MAPK pathway as a 
GTPase-activating protein to increase the hydrolysis of RAS-bound GTP to result in the 
inactive GDP-bound RAS59. 
In addition to mutations in the MAPK pathway, the closely associated PI3K pathway is 
often upregulated. The most common mutation found here is an inactivation of the tumour 
suppressor gene PTEN39. The PTEN protein dephosphorylates phosphatidylinositol (3,4,5)-
trisphosphate to phosphatidylinositol (4,5)-bisphosphate to prevent downstream Akt 
activation60.  PTEN is inactivated in around 10% of primary melanomas, and is frequently 
associated with BRAF-mutant melanomas, thus causing upregulation in both the PI3K and the 
MAPK pathways58,61. 
The final major mutation present in melanoma is in the gene TP53, which codes for the 
protein p53, a regulatory protein involved in DNA repair and apoptosis62. TP53 is one of the 
most commonly mutated proteins across all types of cancer, and it is approximated to be 
mutated in 36.1% of total cancers63. TP53 is mutated in 15-19% of all melanomas, and it is 
more often in combination with BRAF (10%), RAS (20%) and NF1 (30%) mutated cancers than 
triple wild-type, meaning those without any BRAF, RAS or NF1 mutations 50,58,64.  TP53 is a 
tumour suppressor gene and therefore has an inactivating mutation that prevents initiation of 
apoptosis and further enables instability of the genome62.  
 
 
1.5 Grading and Staging of Melanoma 
There are two key systems for classifying cancer, grading and staging. Grading 





staging describes the size of the primary tumour and the extent of the spread. A general tumour 
grading system used for melanoma is shown in Table 1.1 below65: 
Table 1.1 Description of grading system utilized to classify cancer cell abnormality.  
Grading Description 
G1 Well differentiated, look like normal cells. Low grade. 
G2 Moderately differentiated, look partially abnormal. Moderate grade. 
G3 Poorly differentiated and are abnormal. High grade. 
G4 Undifferentiated, extremely abnormal. High grade. 
65 
The staging of melanoma utilizes a tumour-node-metastasis (TNM) system which 
considers the thickness (mm), number of metastatic nodes, and distant metastases of the 
tumours. The most recent version of melanoma staging by the American Joint Committee on 
Cancer considers many more factors for sub-staging, including level of invasion, mitotic rates, 
and ulceration, however the general staging classifications are found in Table 1.2 below5,66,67. 
Table 1.2 Description of melanoma staging and correlating survival rates.   
 Description 5-Year Survival 
Stage 0 Melanoma in situ. Abnormal neoplasm confined to epidermis. - 
Stage I 
Melanoma confined to the skin. Thickness of <1 mm2. Can be 
ulcerated (skin covering is broken open) or not. 
92-97%. 
Stage II 
Melanoma is ulcerated, but not spreading. Thickness is from 1.01 mm 
to 4.0 mm. 
53-81%. 
Stage III 




Melanoma has spread to internal organs, distant lymph nodes, or 
distant skin. 
15-20%. 





1.6 Cancer Metastasis 
 Metastasis is the process where cancer cells breaks off from the primary tumour, travel 
through the blood or lymphatic system, and form tumours in secondary organs. Metastases can 
lead to organ failure, and are responsible for 90% of all cancer deaths68. Melanoma has a high 
propensity to metastasize, and approximately 30% of melanoma patients already have 
metastatic disease upon presentation69. The process of primary tumour cells forming secondary 
malignancies is known as ‘the metastatic cascade’ and follows a series of steps that are generally 
consistent among all cancers: invasion of local tissues, followed by intravasation into lymphatic 
or blood system, extravasation out of the lymphatic or blood vessels into distant sites, and 
finally formation of micrometastases and solid tumours70.   
 For local invasion, tumour cells must exit the local tissues and enter the stroma, 
generally through the basement membrane of the tissues. This stage relies on an important 
process called epithelial to mesenchymal transition (EMT), where cells remodel themselves to 
a cell type that has improved migration and invasive properties. This transition involves the 
alteration of cell adhesion proteins (such as integrins and cadherins), loss of cell polarity, and 
remodelling of the cytoskeleton. This transition is commonly mediated by hypoxia, cytokines, 
or growth factor release71.  
 Once local tissues have been invaded, tumours must enter the local circulatory system 
to travel throughout the body. Primary tumours often form networks of their own vasculature, 
which increases the rate of intravasation. Release of VEGF, which can promote vessel 
leakiness, and matrix metalloproteinase enzymes further help entry of tumour cells  into 
vasculature72. 
 A key factor of the metastatic cascade is survival within the circulatory system. This 
process is stressful to the tumour cells as adhesion-signaling systems are no long available, and 
they are vulnerable to the immune system and general shear forces73. At the site of potential 
metastasis, there are two possible ways that cells are arrested to start invading those tissues. 
The first is the possibility that the tumour cells are mechanically trapped within the 
microvasculature and can no longer move through the vessels, and therefore penetrate through 
the vessels of the secondary organ (i.e. extravasate) and start growing a tumour at that site70. 
The second is a hypothesis that suggests that certain tumour cells have a tropism to other tissue 





 Extravasation of tumour cells is a similar process to intravasation, in which growth 
factors and degradative enzymes break down vessel walls and invade the site of metastasis. 
Formation of vasculature within the metastases is not uncommon, and VEGF plays a key role 
in this process in melanoma56. 
1.6.1 Melanoma Brain Metastasis and the Blood-Brain Barrier (BBB) 
 Brain metastases are the most common form of malignancy in the brain, and one of the 
most devastating complications of cancer. It is estimated that over 100 000 patients develop  
brain metastases in the United States each year and according to autopsy reports, approximately 
25% of patients who die of cancer have brain metastases74,75. Incidence rates are increasing, 
due to improved diagnostics and better treatments of systemic disease76. Although all cancer 
types can metastasize to the brain, lung cancer, breast cancer, and melanoma constitute the 
majority of brain metastases, accounting for 67-80% of cases77,78. Of these three, melanoma has 
the highest propensity to travel to the brain, so although it does not account for the most cases 








Figure 1.4: Pie chart of the different primary cancers from which brain metastases originate. The chart 
is based on data published in Nayak, 2011.  
 It has been estimated that 20-54% of melanoma deaths are due to brain metastases, 
although autopsy studies show that up to 70% of melanoma patients have brain metastases79-82. 
If untreated, these patients have median survival times ranging from 3-6 months80,83. Aggressive 
treatment (see Chapter 1.7) has prolonged the survival to 12-22 months due to improvement of 
targeted treatments, depending on the initial prognosis84,85. Melanoma patients are more likely 
to have multiple brain metastases and the majority of these patients will also have metastases 
to other organs77,83. Brain metastases are extremely fatal, as any damage to the central nervous 





Chemotherapeutic treatment of brain metastases is usually not effective, due to the 
blood-brain barrier (BBB), which effectively prevents more than 98% of small molecules from 
entering the brain86. The BBB is a highly restrictive barrier between the blood vessels and the 
brain parenchyma, preventing non-selective transport of molecules through the vasculature. 
The BBB consists of endothelial cells connected by tight junctions87. Pericytes and smooth 
muscle cells rest on a tight basement membrane around the vasculature, and microglia act as 
local immune cells, in addition to circulatory immune cells, which may enter brain tissues under 
certain neurological conditions88.  Astrocytic end feet surround the endothelial tubes to provide 
structural integrity and act as a cellular link between the neurons and blood vessels87. This 
restrictive barrier to the brain only allows penetration of molecules less than around 400-500 
Da, although hydrophobicity charge and shape of the molecules also play a role89.   
1.7 Treatment of Melanoma Brain Metastases 
 Although there are many different treatments offered to patients with melanoma brain 
metastases, the poor survival rates clearly indicate their lack of effectiveness. Brain metastases 
are commonly treated with surgery, radiotherapy, radiosurgery, and chemotherapy90. Surgical 
intervention is regularly performed on patients with one or several lesions, if they are localized 
in accessible areas, and not too close to critical brain structures. Most melanoma patients have 
multiple lesions at diagnosis, and the most life-threatening metastases are therefore chosen for 
Figure 1.5 Illustration of the blood-brain barrier. The endothelial cells only contain tight junctions, allowing 
no passive diffusion from blood. Smooth muscle and pericytes structurally support the endothelial cells and 
are surrounded by two layers of basal lamina (BL1 and BL2) to ensure stability and help mediate blood 
flow. Astrocyte end feet help maintain the barrier and act as a signalling link between the BBB and neurons. 





operation. Resected tumour material is also used for histologic assessment to determine a more 
personalized route of treatment90.   
 In the past whole brain radiotherapy (WBRT) combined with corticosteroids has been 
one of the typical initial treatments for brain metastases, either administered alone or after 
surgery91. Corticosteroids are administered only to reduce symptoms, such as edema and 
seizures, as they do not decrease tumour burden. Long term use of steroids can cause several 
side effects ranging from moderate such as increased blood sugar, to life threatening such as 
gastrointestinal ulceration92. WBRT also is a very non-targeted treatment and therefore 
neurocognitive decline is a major side effect, reducing verbal, recall, and fine motor skills90.  
Stereotactic radiosurgery (SRS) has recently emerged as an effective treatment strategy 
for brain metastases. SRS is a local radiation treatment, delivering focused, single high-dose 
radiation through gamma or x-ray beams93. When compared to WBRT, SRS does not 
demonstrate a statistically significant difference in overall survival (7.3 months for SRS vs. 7.2 
months for WBRT) in patients with up to ten lesions, but it causes much less adverse side effects 
during and after treatment such as edema and leukoencephalopathy94. However, the 
development of radiation necrosis 7-12 months after treatment is more common in SRS than in 
WBRT95. Radiation necrosis, occurring in 10-25% of SRS-treated patients, includes 
psychomotoric impairment, seizures, memory loss, and personality changes96-98.  
 Immunotherapy is a type of targeted therapy that aims to induce an immune response 
within the tumour. Ipilimumab is a monoclonal antibody blocking CTLA-4 that causes 
continuous activation of T-cell targets in tumour cells. These antibodies are not able to cross an 
intact BBB, but active T-cells can90. In a phase II clinical trial of patients with advanced 
melanoma and brain metastases, a monoclonal antibody blocking CTLA-4 called ipilimumab 
showed a CNS response rate of 16%, with a median survival of 7.0 months99. Pembrolizumab, 
a monoclonal antibody activating programmed cell death protein 1 (PD-1) on lymphocytes, was 
used in a phase II trial with asymptomatic melanoma brain metastases patients. There was a 
26% response rate and some patients even lived to 24 months, however there were adverse side 
effects such as controllable seizures and cerebral edemas100. While immunotherapy does seem 
promising, it has been speculated that patients put onto steroids may not respond to the therapy, 






 Finally, the most promising advancement in the treatment of melanoma brain metastases 
is therapies targeting the proteins that cause dysregulation in major growth pathways. As 
discussed in Section 1.4, melanomas often have activating mutations in the MAPK and PI3K 
pathways. Dabrafenib and vemurafenib both target the BRAF protein and in clinical trials, the 
use of these drugs has resulted in increased survival compared to controls, with a median life 
expectancy of 8 months and 5.3 months, as well as response rates of 39% and 16%, 
respectively101,102. Despite their initial effectiveness, a major complication of these drugs is the 
development of resistance after around 6 months of treatment103. Melanoma brain tumours have 
the capacity to activate underlying mechanisms that help confer resistance to these treatments, 
so combination treatments are also being attempted to inhibit multiple pathways. These 
mechanisms include changing signaling proteins from BRAF to CRAF or ARAF, activating 
tyrosine kinase receptors to promote pathways involved in survival, and mutational alterations 
in other major effector proteins104. Targeting both BRAF and MEK proteins with dabrafenib 
and trametinib or vemurafenib and cobimetinib is currently being evaluated105-107. More 
recently, targeting the PI3K pathway has been of interest, and there is currently an ongoing 
study evaluating the effectiveness of the pan-PI3K inhibitor buparlisib in patients with brain 
metastases108.  
Multimodal treatments used to treat the primary cancer have also been tested on brain 
metastasis patients, including combined targeted therapies and immunotherapies109-111. There 
have been clinical trials evaluating immunotherapy in combination with WBRT or SRS 
treatment, with varying results from no improvement compared to that of single modality, to 
significantly increased life expectancy112-114.    
1.8 PI3K  
 PI3K proteins are a large family of lipid kinases that are divided into three main classes. 
Class I PI3Ks are the most common form and most involved in cancer. Class I converts 
phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3) and is activated by receptor tyrosine kinases (RTKs). Class I PI3Ks are heterodimers 
made up of a regulatory unit that receives the activating stimulation and a catalytic subunit that 
detaches and has intrinsic enzymatic ability. There are four isoforms of catalytic subunits 
denoted by their 110 kDa size: p110α, β, δ, and γ. P110α and p110β are constituently produced 
in all cells, while p110δ and  p100γ are found in leukocytes and have little importance in 
melanoma115.  Class II PI3Ks consist only of a single enzymatic subunit and preferentially 





involvement in clathrin-mediated endocytosis. Class III PI3Ks are structurally similar to Class 
I, but their substrate is exclusively phosphatidylinositol, and they are involved in protein 
autophagy115. There is a distant Class IV that does not fit into the category of ‘true’ PI3Ks but 
includes distantly-related serine/threonine kinases116.  
As mentioned in Section 1.4, the PI3K signaling pathway is often upregulated in 
melanoma. In brief, the PI3K pathway is a cascade of regulatory proteins, both positive and 
negative, that regulates essential functions such as angiogenesis, metabolism, transcription, 
protein synthesis, and apoptosis117. PI3K is one of the first modulatory proteins in the pathway 
and is stimulated by an RTK, either directly or through adaptor molecules. PI3K then converts 
PIP2 into PIP3, which allows binding and activating of PDK1 and Akt, and subsequent 
downstream activation of other effectors such as mTOR117. 
Because of its involvement in so many important regulatory functions, PI3K is of major 
importance in cancer, and often has mutations in either PI3K itself, PTEN, or an upstream RTK. 
The major effect in PTEN-deleted cells is overactivation of Akt, whereas in PI3K-mutated cells 
there are increased interactions with lipid membranes118. Most often mutations in cancers are 
found in the p110α subunit (gene: PIK3CA), but there is also evidence of p110β (gene: PIK3CB) 
activation in HER2-amplified breast cancers119.  
1.8.1 PI3K-Selective Inhibitors 
In clinical treatment, three major strategies for PI3K pathway inhibition are currently in 
use: dual PI3K/mTOR inhibition, pan-PI3K inhibition, or isoform-selective inhibition. 
Promising results after using the pan-PI3K inhibitor buparlisib have been reported in melanoma 
brain metastases120,121. However, pan-PI3K inhibitors have relatively high rates of adverse side 
effects due to off-target toxicity such as hyperglycaemia, gastrointestinal intolerance, and 
stomatitis122-124. It has been demonstrated that selective inhibitors have improved specificity 
and reduced toxicity, and therefore a maximal inhibitory dose without severe side effects may 
be achieved more easily123,125,126. These results may provide the opportunity for combination 
therapies targeting multiple signaling pathways. 
 There are few FDA-approved selective inhibitors for PI3K isoforms. A Class Iγ 
inhibitor for lymphoma patients, and only last year a PI3Kα inhibitor alpelisib was approved 
treatment in breast cancer patients; however, it has been proven to not cross the blood brain 
barrier, and has excluded patients with brain metastases in some clinical trials127,128. There are 





focusing on melanoma specifically with PTEN loss129-132. The focus is mainly on breast cancer 
as up to 70% of breast cancers have PI3K activation and 30% have PI3Kα activating 
mutations133.  PI3K reactivation is involved in 20% of melanoma patients with resistance to 
BRAF and MEK inhibitors134.  PTEN deletion is often found in combination with BRAF 
mutations, but not combined with NRAS mutations. In cases of melanoma with BRAF 
activation and PTEN loss, inhibition of BRAF or MEK is less effective than combined 
inhibition135. PI3K pathway inhibitors have been reported to be effective in BRAF-mutant 
cancer cell lines, even in those without any PI3K pathway abberations136,137. They have also 
been found to be effective in NRAS mutant melanomas, as Ras is a stimulating protein for both 
MAPK and PI3K pathways. It should be noted that in melanomas with PTEN loss, p110β seems 
to be the more active isoform, while those with RTK-driven signaling have more reliance on 
the p110α isoform137.  
1.8.2 HS-173 
 HS-173 is an extremely potent PI3Ka inhibitor with an IC50 dose of 0.8 nM in cell-free 
assays138. The molecular weight is 422.46 Da, and the molecule acts a competitive inhibitor by 
binding to the ATP-site of PI3K138. It has been found to reduce proliferation and angiogenesis, 
while promoting apoptosis in breast cancer, liver cancer, pancreatic cancer, and melanoma139-
141. It has been shown that HS-173 inhibits tumour vascularization by decreasing the expression 
of HIF1a and VEGF under hypoxic conditions. By inhibiting the PI3K pathway, it decreases 
EMT transition and metastasis to the liver, lung, and lymph nodes by supressing Akt-driven 
morphology changes that contribute to cell invasiveness141. The anti-tumour effect has been 
shown in both in vitro and in vivo models, with no body weight loss in mouse models. While 
decreasing tumour vascularization, HS-173 also helped to increase vascular morphology by 
reducing leakiness and further tumour invasiveness in xenograft and metastatic models140. 
Finally, HS-173 has been shown to promote radiosensitivity in pancreatic cancer animal 
models, with the combination of HS-173 and radiation having a synergistic effect. While 
promoting apoptosis in tumours, the remaining live cells were found to have a G2/M phase cell 
cycle arrest, decreasing the cells’ ability to repair and synthesize DNA, leading to radiation 
sensitivity142. In a high-throughput study evaluating effective PI3Ka inhibitors for combination 
therapies, HS-173 was selected as the most effective and specific PI3Ka inhibitor143. These 
effects suggest that HS-173 is a good candidate for evaluating the effectiveness of PI3Ka 







The main aim of this Master thesis was to evaluate the in vitro effects of the PI3Kα 
inhibitor HS-173, on four human melanoma brain metastases cell lines. 
 
Six sub-aims were defined for the work in this Master thesis: 
 
1. To evaluate the effect of HS-173 on cell viability in monolayer cultures. 
2. To study potential morphological changes induced by HS-173, using light 
microscopy.  
3. To evaluate the effects of HS-173 on cell proliferation and migration, using a scratch 
wound assay. 
4. To investigate potential apoptotic effects after HS-173 exposure, by flow cytometry.  
5. To determine the potential effects on PI3K signaling after HS-173 exposure, using 
western blot.  
6. To evaluate the effect of HS-173 on cell viability on tumour cells grown as 3D 






3.0 Materials and Methods 
3.1 Cell Lines  
 Experiments were conducted with the four following cell lines: H1, H2, H3 and H10. 
All cell lines were developed in our laboratory from resected tumours of four patients with 
malignant melanoma brain metastases. Before tumour material collection, informed written 
consent was obtained from each patient. The BRAF mutation status of these cell lines was 
investigated by performing massive parallel sequencing of tumour DNA. Our previous results 
showed that all cell lines contained a BRAF mutation, with H1, H2 and H10 containing a V600E 
mutation and H3 showed a novel melanoma mutation L577F121. The origin of the cell lines was 
verified through short tandem repeat (STR) fingerprinting before use, and frequently tested for 
mycoplasma during the thesis work.  
 
3.1.1 General Culture of Cells  




Dulbecco’s Modified Eagle Medium Sigma-Aldrich Inc., St. Louis, MO, USA 
 
10% heat-inactivated newborn calf serum  Thermo Fischer Scientific, Waltham, MA, USA 
 
5 µg/mL Plasmocin  Invitrogen, Toulouse, France 
 
2% L-glutamine  BioWhittaker, Verviers, Belgium 
 
100 IU/mL penicillin BioWhittaker, Verviers, Belgium 
 




10X Dulbeccos phosphate-buffered saline Sigma-Aldrich Inc. 
  Autoclaved MilliQ water - 
 
All cells were cultured in ALT-DMEM. Cells were kept in T175 culture flasks (Nunc, Roskilde, 
Denmark) in a standard incubator at 37 °C, 100% humidity and 5% CO2
 .  
Cells were trypsinated at 75-80% confluency using 0.25% Trypsin/EDTA 
(BioWhittaker). Prior to trypsinization, flasks were washed with 8 mL of 1X PBS prior to 
adding 4 mL of trypsin and placing in the incubator for 2 mins. Trypsin was neutralized using 
6 mL of ALT-DMEM and cells were resuspended by pipetting up and down before adding to 
fresh flasks for counting.  
The cells were counted before in vitro experiments were performed. 10 μL of cell 





Germany) and mixed with 10 μL of Trypan blue stain (Life Technologies, OR, US) to stain 
dead cell nuclei. 10 μL of the solution was then transferred into each side of a cell counting 
chamber slide (Thermo Fisher, Invitrogen) and inserted into the Countess Automated Cell 
Counter (Thermo Fisher, Invitrogen). The mean value from two individual counts of live 
cells/mL was used to calculate the mean number of cells/mL in the cell solution. 
All cells were only used for ten passages after thawing, with one passage being 
considered as one trypsinization.  
 
3.1.2 Thawing and Freezing of Cells  
Cells were thawed by hand and immediately pipetted into a T75 cm2 flask containing 
15 mL of pre-warmed culture media and gently resuspended prior to incubation at 37 °C, 5% 
CO2 and 100% humidity. 
 Cells were frozen when a T175 cm2 flask was 70-80 % confluent. Cells were first 
passaged as described in 3.1.1, and the 10 mL cell solution was transferred to a Falcon tube 
(Thermo Scientific). The cell solution was centrifuged at 900 x g for 4 mins, the supernatant 
was removed, and the cell pellet was resuspended in 4mL of cold freezing medium. The freezing 
medium was prepared by mixing 1:1 solution of ALT-DMEM + 20% FBS and PBS + 20% 
DMSO. 1 mL aliquots of cells were frozen in cryotubes (Nunc, Roskilde, Denmark) at -80 °C 
in a Mr. Frosty Freezing Container (Thermo Scientific, Nalgene) overnight and transferred to a 
cryotank for long term storage.  
3.2. Experimental Preparation  
 
3.2.1 Drug Preparation: HS-173 PI3Kα inhibitor  
Table 3.2: Information about the HS-173 inhibitor, taken from the Selleck Chemicals 
webpage138.  
Synonym: N/A 
Application: HS-173 is a potent PI3Kα inhibitor 
CAS Number: 1276110-06-5 
Purity: 99.6 % 
Molecular weight: 422.46 (Da) 
Molecular formula: C21H18N4O4S 





Physical state: Solid  
Solubility: 84 mg/mL (198.84 mM) in DMSO, insoluble in water 
Storage:  -80 °C 
 
The drug was received as a powder and diluted to a stock solution of 100 mM in DMSO, 
aliquoted in 30 µL and stored at -80 °C. For experiments, stock solutions were thawed in a 37 
°C water bath and diluted in ALT DMEM to the required concentrations.  
3.3. Monolayer Viability Assay 
The cell lines H1, H2, H3 and H10 were seeded in 96 well plates (Nunc) at a 
concentration of 5.0x103 cells/100 µL in each well and left to incubate overnight to make sure 
the cells were attached to the surface. After 24 hrs, 100 µL of HS-173 was added at the 
following final concentrations: 1.0x10-5 µM, 1.0x10-4 µM, 1.0x10-3 µM, 1.0x10-2 µM, 0.1 µM, 
0.5 µM, 1 µM, 5 µM, 10 µM and 50 µM. Each concentration was added to a whole column in 
the plate (8 repetitions). As negative controls, 100 µL of growth medium without drug was 
added into wells containing cells, as well as DMSO control at the highest dose (0.05% v/v) to 
ensure inhibition was caused by HS-173 and not the diluent. Another column contained only 
medium and was used to calculate the background signal from the medium which was deducted 
from the results. After addition of inhibitors, the cells were incubated for 72 hrs. Then, 20 µL 
of 0.1 mg/mL Resazurin (Sigma-Aldrich Inc.) was added into each well, and the plate was 
incubated for 4 additional hrs. Absorbance was measured using a scanning multi-well 
spectrophotometer (VictorTM 3 1420 multi-label counter, Perkin Elmer, Waltham, MA, USA) 
at wavelengths of 560/590 nm. Background was controlled for by subtracting averaged blank 
values. The negative control was set to 100% viability, and the drug-treated samples were 
normalized to the negative control accordingly.   
The measured, normalized values were analyzed using GraphPad Prism 8 (GraphPad 
software, Inc., La Jolla, CA, USA) by transforming the X-values logarithmically for further 
processing of the data. A normalized response – variable slope logistic nonlinear regression 
analysis was fitted to the data to calculate IC50 of HS-173 for each cell line. The resulting curves 
demonstrated the cell viability relative to the drug concentration. Three replicates were done 
for each cell line. IC50 values were used to establish four HS-173 concentrations to use for each 
cell line, shown in Table 3.3. These concentrations were designed to establish a therapeutic 
window of doses around each independent IC50 while still having two comparable doses across 






Table 3.3- HS-173 concentrations for each cell line used for the duration of this thesis unless stated 
otherwise.  
Cell Line Concentrations used 
H1 0.1 µM, 0.3 µM, 0.5 µM, 1.0 µM 
H2 0.05 µM, 0.1 µM, 0.3 µM, 0.5 µM 
H3 0.05 µM, 0.1 µM, 0.3 µM, 0.5 µM 
H10 0.3 µM, 0.5 µM, 1.0 µM, 1.5 µM 
 
3.4. Scratch Wound Healing Assay 
The effect of HS-173 on the migratory capacity of the cell lines were studied using a 
live cell scratch wound assay. H1, H2, H3 and H10 cells were seeded in 8 replicates at a density 
of 3.0x104 cells/well in Essen BioScience ImageLock 96-well plates (cat. no. 4379, Essen 
BioScience Ltd., Hertfordshire, UK) and allowed to incubate for 48 hrs to obtain confluent 
cultures. A wound-maker tool was used to create wounds within all wells, which were then 
washed 2 times with pre-warmed media. HS-173 was added in concentrations shown in Table 
3.3, in addition to a control with only growth medium.  Images were taken every 2 hrs for 72 
hrs using the 10x objective in the IncuCyte Live Cell Imaging System (Essen BioScience Ltd.) 
with subsequent analyses performed using the IncuCyte Scratch Wound Cell Migration 
Software Module (cat. no. 9600-0012, Essen BioScience Ltd.) to find relative wound 
confluency.  Each experiment was repeated three times. 
 
3.5. Cell Morphology Imaging  
 H1, H2, H3 and H10 cells were seeded at 1.5x105 cells/well and incubated for 24 hrs. 
HS-173 was then added to each cell line according to Table 3.3 in addition to untreated cells. 
The cells were incubated for an additional 72 hrs. A Nikon TE2000 inverted light microscope 
(Nikon Instruments Inc., NY, USA) was used to capture images from each drug concentration 
using the 10X objective. Three representative images were taken from each well, and the 








3.6. Western Blotting  
Table 3.4- Reagents used for cell lysis.  
Reagent Name  Company 
RIPA Lysis Buffer  
 
 
Radioimmunoassay precipitation buffer 
(RIPA) Thermo Fisher Scientific 
 
10% Protease + Phosphatase inhibitors  
 
Protease + Phosphatase Inhibitors  
 
 
1 tablet protease inhibitors Roche, Sigma-Aldrich Inc. 
 
1 tablet phosphatase inhibitors Roche, Sigma-Aldrich Inc. 
  1 mL RIPA Buffer  Thermo Fischer Scientific 
 
Table 3.5- HS-173 concentrations for each cell line used for the western blot preparations. 
Cell Line  Concentration of HS-173 
H1 1.0 µM 
 
H2 0.5 µM 
 
H3 0.5 µM 
  H10 1.0 µM 
 
To observe the inhibition effect of HS-173 on the PI3K pathway, cells from H1, H2, H3 
and H10 cells treated with HS-173 were subjected to western blotting. Cells were seeded at 
1.5x106 cells/10 cm dish and treated after 24 hrs with concentrations of HS-173 shown in Table 
3.5. Negative controls were grown in medium only. Cells were then washed twice with cold 
PBS, removed from the plates with a cell scraper and lysed after either 24, 48 or 72 hrs using 
RIPA buffer supplemented with 10% protease and phosphatase inhibitors. Cell debris was 
pelleted by spinning the samples at 13 500 x g for 10 mins at 4 °C. The protein concentration 
in each lysate was determined using a Pierce BCA Protein Assay Kit (Pierce Biotechnology, 









Table 3.6- Reagents used for running, transfer and blotting of SDS-PAGE.  
Reagent Name  Company 
1X Tris-glycine Running Buffer 
 
 
10X TGS buffer Bio-Rad laboratories AB, Oslo, Norway 
 
dH2O - 
1X Tris-Glycine transfer buffer 
 
 














5% blocking buffer 
 
 
5% Skim milk powder Bio-Rad laboratories AB 
 




10X TBS - 
 




10X TBS (Tris-Buffered Saline) 
 
 
0.2 M Tris-HCl (pH 7.5) Bio-Rad laboratories AB 
 
1.5 M NaCl Bio-Rad laboratories AB 
  dH2O - 
 
Table 3.7- Antibodies used for immunostaining of SDS-PAGE.  
Antibodies  Dilution Company  
Anti-Akt 1:1000 Cell Signaling, Danvers, MA, USA 
Anti-p-Akt (Ser473) 1:1000 Cell Signaling 
Anti-mTOR  1:1000 Cell Signaling 
Anti-p-mTOR(Ser2448) 1:1000 Cell Signaling 
Anti-GAPDH  1:10 000 Invitrogen, OR, USA 
Secondary anti-rabbit mouse  1:10 000 Invitrogen 
 
The samples were thawed on ice and 30 µg total protein of each sample was 





80 V for 30 min for protein stacking, and then at 100 V for protein separation, in Tris-glycine 
running buffer. Proteins separated on gels were blotted onto 0.2 µM pore nitrocellulose 
membranes (Bio-Rad laboratories AB) at 100 V for one hr (10% gel) or two hrs (6% gel) on 
ice using the BioRad Mini Trans-Blot transfer system and Tris-Glycine transfer buffer. 
Membranes were stained with Ponceau stain for 2 mins to visualize total protein bands before 
cutting to separate proteins of interest for blotting and blocking in 5% blocking buffer for 1 hr 
at room temperature on a see-saw rocker (Stuart Equipment, Cole-Parmer, Staffordshire, UK). 
Primary immunostaining on membranes was performed overnight at 4°C on a rocker using 
primary antibodies diluted in blocking buffer and against: Akt, p-Akt (Ser473), p-mTOR 
(Ser2448), mTOR and GAPDH. Membranes were washed 2 x 5 mins and 2 x 10 mins in TBS-
Tween Buffer before adding secondary anti-rabbit mouse diluted 1:10 000 in blocking buffer 
for 1 hr at room temperature using a rocker. Membranes were then washed 4 x 5 mins and 2 x 
10 mins before visualizing using the LAS3000 and chemiluminescent detection kit, either 
SuperSignal West Femto (Pierce Biotechnology) or SuperSignal West Pico (Pierce 
Biotechnology). 
 
3.7. Flow Cytometry  
3.7.1 Flow Cytometry Theory 
Flow cytometry is a technique that can quantify cell properties including cell size, cell 
number, cell cycle and protein expression. Cells are stained with fluorophores/tagged antibodies 
or fluorescent dyes to detect proteins or other structures of interest. 
Flow cytometry consists of three main components: fluidics, optics and electronics (Fig. 
3.1). Initially the cell sample is taken up into the fluidics system and transported to the flow cell 
in a single cell suspension to pass through a laser beam. Having a single cell suspension is 
important in order to ensure investigation of individual cells or “events”. The optical system is 
comprised of multiple lasers, filters, mirrors and detector lenses144. There are two illuminating 
lasers that determine non-fluorescent properties of the cells. Forward scatter (FSC), diffracted 
parallel from the light, determines the size of each cell. Side scatter (SSC), diffracted from 90o, 
determines the internal complexity, or granularity, of each cell145. The rest of the lasers function 
to excite any fluorophores associated with each cell.  All of these emissions are detected by a 
multitude of fluorescence detectors, or photomultiplier tubes (PMTs), and sent to the computer. 
The electronic system then digitizes the detected emissions to process into quantifiable data that 






In multiplexed experiments, where cells are tagged with more than one fluorophore, a 
mathematical method called compensation is required prior to analysis.  
 
 
Fluorophores often have some overlap in their emission spectra that can be registered 
in a detector meant for another fluorochrome, a phenomenon known as spillover (Fig. 3.2). This 
Figure 3.1: Schematics of a flow cytometer. Simplified diagram of the main components in a flow 
cytometer. Samples enter from the top as a cell suspension through the flow chamber and are arranged 
into single file as they pass through the laser (light source). Each cell scatters light as forward scatter 
(FSC) and side scatter (SCC), and emits fluorescent light if tagged with a fluorophore. Dichroic mirrors 
act to filter specific wavelengths to the proper detectors. Detected emissions are transferred to the 
processing system. Analyzed cells may be either sorted based on fluorescent characteristics or passed into 
a waste bin. Schematic from https://www.cellsignal.com/contents/_/overview-of-flow-cytometry/flow-cytometry-
overview 
Figure 3.2: Emission spectra and compensation of FITC and PE. The emission spectra of FITC and PE, 
and representation of their spillover captures by each respective filter. Blue shows the spillover from PE 
into FITC detection, and red represents spillover from FITC into PE detection. Single FITC and PE stained 






overlap, if not controlled for, can skew data and give false readings in different fluorescence 
channels. Therefore, when using more than one fluorophore, controls are required for proper 
analysis. To properly determine the amount of overlap in fluorophores used, a compensation 
matrix is made to control for any spillover in the final analysis. Single fluorophore controls are 
used (i.e. FITC only, PE only) and the software can then calculate the overlap and normalize 
the data accordingly146.    
3.7.2 Apoptosis Assay 
An apoptosis assay was performed to assess the apoptosis-inducing ability of HS-173 
on the H1, H2, H3 and H10 cell lines. To detect the stages of apoptosis of the cells, FITC-
tagged Annexin V and propidium iodide (PI) were analyzed. Annexin V, a phospholipid-
binding protein, has a high binding affinity to phosphatidyl serine (PS) which is located on the 
internal leaflet of the membrane in viable cells. PI is a membrane-impermeable nucleic acid 
binding dye.  
In viable cells, neither stain will bind as PS and nucleic acids are located inside the cell. 
In early apoptosis, the membrane is still intact, but PS has shifted to the external membrane, 
therefore the cells will be FITC +. In late apoptosis, the membrane is breaking down, and is 
therefore permeable by PI, therefore these cells will be FITC +/ PI +. If cells are necrotic, there 
is a complete membrane breakdown and cells may only be PI +. However, it is difficult to 
distinguish between late apoptotic and necrotic cells; therefore these categories was combined 
for analysis147. 
 Cells were seeded at a density of 1.2x105 cells/well in six-well plates (Nunc). After 24 
hrs, cells were treated with doses as shown in Table 3.3 for 72 hrs. Culture medium was 
removed and collected and rinsed two times with cold PBS. As a positive control for apoptosis, 
4 µL of 30% H2O2 was added to one well per cell line for 2 hrs. Cells were trypsinated, collected 
and centrifuged at 900 rpm for 4 mins. Following this cell pellets were then rinsed with cold 
PBS and centrifuged a second time at 900 rpm for 4 mins. 200 µL of 1X Annexin V binding 
buffer was added into each sample, followed by staining using 5 µL of AlexaFluor488 Annexin 
and 1uL of propidium iodide (PI; AlexaFluor®488 Annexin v/dead cell apoptosis kit; 
Molecular Probes, Life Technologies). Untreated cell controls included: PI staining only, 
Annexin-FITC staining only, no staining, and double staining apoptosis positive control. 
Samples were placed on ice before being analyzed using a BD LSR Fortessa flow cytometer 
(BD Bioscience). Data analysis was performed using FlowJo 10.6.1 (Tree Star Inc., Ashland, 






Figure 3.3: Gating path for flow samples. A) Gating out debris. This gate is set to include all live cells 
as well as possible dead cells and apoptotic bodies. B) Gates out doublets. This gate is also set wide to 
accommodate for increase granularity and size distribution of apoptosing cells. C) Gating of 
fluorescence quadrants based on single stain controls and confirmed populations with positive dead cell 
control.  
3.9. Statistical Analysis  
All statistical analyses were done using GraphPad Prism v8 (GraphPad Software, Inc.). Scratch 
wound data were analyzed using an ordinary one-way ANOVA with Dunnett’s multiple 
comparisons test, and flow data were analyzed with an ordinary two-way ANOVA with 











4.1 Viability Assays  
4.1.1 HS-173 effectively decreases cell viability      
A resazurin cell viability assay was performed to determine the IC50 doses of HS-173 in our 
four cell lines by exposing them to increasing drug concentrations during a 72 hrs incubation 
period.  
As shown in Fig. 4.1, HS-173 reduced the cell viability in all four cell lines in a dose-dependent 
manner, even at nM concentrations. All cell lines displayed a consistent response to the 
inhibitor, although H2 and H3 viability declined rapidly once concentrations surpassed 0.1 µM 
and viability remained extremely low at all higher concentrations. Regarding the H1 and H10 
cells, the sigmoidal curve fit was not as steep as for H2 and H3 cells, indicating higher resistance 
towards drug treatment. This was also reflected in the IC50 doses (Table 4.1).  
Table 4.1: Mean IC50 doses of each cell line following the 72 hrs resazurin viability assay. N=3.  





Table 4.1 displays the calculated mean IC50 doses of all cell lines. IC50 is defined as the 
concentrations where 50% of cell growth is inhibited. These results were consistent across cell 
lines, ranging from 0.15-1.0 µM. H2 was the most sensitive to the drug, while H10 was the 
most resistant.  All cell lines were susceptible to the drug at very low concentrations. These 
Figure 4.1: Representative dose-response curves of H1, H2, H3 and H10 cell lines after exposure to 
increasing doses of HS-173 for 72 hr. Cells were seeded in a 96 well format at 5x103 cells/well. After 24 
hr, HS-173 was added in increasing concentrations from 0.01nM – 50µM.  After 72 additional hr, viability 






IC50 doses were utilized to establish a range of effective doses tailored to each cell line in 
subsequent assays, while keeping two doses comparable across all cell lines.  
4.1.1 HS-173 induces morphology changes across all cell lines      
 The effects of HS-173 on cell morphology of H1, H2, H3 and H10 cell lines were 
studied by light microscopy.  
In general, the cell density decreased with increasing doses of HS-173.   Untreated H1 cells 
(Fig. 4.2) exhibited an adherent, elongated and spindle-like morphology with smooth 
membranes. At 0.1 µM, changes in cell morphology were not seen, however at 0.3 µM, cells 
begin to lose their adherence, and those still adhered have fewer appendages. At 0.5 µM, large 
amounts of floating cells were apparent, and adhered cells exhibited more rounded cell-shapes, 
as well as more granular membranes. At the highest concentration, 1.0 µM, cell debris could be 
seen floating in the media, in addition to non-adherent cells. The few cells that still adhered 
were flat with granular membranes, and almost no spindle-like appendages were visible.  
 
Untreated H2 cells (Fig 4.3) showed a similar morphology to untreated H1 cells, 
although they were a bit flatter and had much more visible cellular structures. At the lowest 
concentrations, 0.05 µM, there were no visible morphological changes. At 0.1 µM, although 
there were a few cells that started to lose their spindle-like morphology, the majority of cells 
Figure 4.2: Images demonstrating H1 cell morphology changes under presence of increasing 
concentrations of HS-173. Cells were seeded in 6-well plates and exposed to HS-173. Images were taken 
with a Nikon TE2000 inverted microscope after 72 hrs of treatment. Scale bar=300 µm. UT: Untreated 
Figure 4.3: Images demonstrating H2 cell morphology changes under presence of increasing 
concentrations of HS-173. Cells were seeded in 6-well plates and exposed to HS-173. Images were 
taken with a Nikon TE2000 inverted microscope after 72 hrs of treatment. Scale bar=300 µm. UT: 
Untreated. 
            UT              0.05 µM               0.1 µM             0.3 µM             0.5 µM 





looked similar to the control. Cells treated with 0.3 µM exhibited a large population of floating 
cells, as well as debris floating in the growth medium. Cells that were adhesive had both 
spindle-like and rounded morphology. At the highest concentration, 0.5 µM, the cell 
morphology was similar to 0.3 µM, lots of floating cells and cell debris, as well as a population 
of adhered cells, although at this concentration there was a noticeably smaller number of cells.  
 
Untreated H3 cells (Fig 4.4) were flat fibroblast-like cells, with a granular membrane, 
and although they did not show as extensively spindle-like structures as seen for H1 and H2 
cells, they were quite elongated. They also formed a tight monolayer of cells with little space 
in between each cell. The lowest concentrations, 0.05 µM, showed no major morphological 
changes. Wells treated with 0.1 µM had some floating cells visible, and adherent cells started 
pulling away from each other to form a space in between single cells instead of a tight 
monolayer like seen for the untreated cells. Those treated 0.3 µM however, showed a more 
extreme case of this, with a higher amount of floating cells, and a more scattered adherent cell 
growth. At the highest concentration, 0.5 µM, there were much less cell adhered than in the 
control, and there was also a very large amount of small cell debris scattered along the bottom 
of the plate. Adhered cells also exhibited a rounding of the membrane, although there were still 
cells that displayed the typical elongated form.  
 
 
Figure 4.4: Images demonstrating H3 cell morphology changes under presence of increasing 
concentrations of HS-173. Cells were seeded in 6-well plates and exposed to HS-173. Images were 
taken with Nikon TE2000 inverted microscope after 72 hrs of treatment. Scale bar=300 µm. UT: 
Untreated. 





Untreated H10 cells (Fig 4.5) also showed a fibroblast-like morphology, with spindle features 
and a relatively flat cell shape. They also grew in a sporadic, overlapping manner, unlike the 
H3 cells.  Even at the lowest dose of HS-173, 0.3 µM, there was a much higher amount of 
rounded, floating cells, but the adhered cells still seemed relatively unaffected. At 0.5 µM much 
of the same was seen, a large amount of floating cells, and the adhered cells started to take on 
a slightly less elongated shape and had a shortened oblong morphology. The appearance at 1.0 
µM was similar to 0.5 µM with a lower cell density. There was not a noticeable difference 
between the final two concentrations 1.0 µM and 1.5 µM. Interestingly, unlike the other cell 
lines, although there were many cells floating, the amount of floating and adhered cells 
combined was not noticeably different than the control, where in the other cell lines we saw a 
marked decrease in the cells overall. In H10, there seemed to be still many whole cells in the 
media, and less debris compared to the other three cell lines.  
4.2 HS-173 decreases cell proliferation and migration in H1, H2, H3 
and H10 cell lines 
To assess the effect of HS-173 on the proliferation and migration of all cell lines, a 
wound-healing assay was performed. 
Figure 4.5: Images demonstrating H10 cell morphology changes under presence of increasing 
concentrations of HS-173 after 72 hrs. Cells were seeded in 6-well plates and exposed to HS-173. Images 
were taken with Nikon TE2000 inverted microscope after 72 hrs. Scale bar=300 µm. UT: Untreated. 






As seen in Fig. 4.6. A, untreated H1 cells fully closed the wound created after around 
50 hrs and reached a plateau of growth over the rest of the experiment. Cells outside the scratch 
were quite confluent and floating cells were observed, similar to what is typical in a confluent 
cell culture flask. The cells that migrated over the wound were elongated with a smaller amount 
of floating or rounded cells. At the lowest dose, 0.1 µM, the wound was closed entirely although 
it did take slightly longer than in the untreated (Fig. 4.6 B). Visually, there were much more 
rounded cells in the sample. Wells treated with the highest three concentrations did not 
successfully close the gap, and as the drug concentration increased, the migration into the 
wound lowered significantly (Fig. 4.6 C). There was also a very noticeable difference in cell 
morphology; the cells were almost all rounded. At the highest dose, 1.0 µM, the outer cells had 
an even lower confluency than at the initial timepoint.  
Figure 4.6: Migration of H1 cells during exposure with varying concentrations of HS-173. Cells were 
seeded at 30 000 cells/well in 96-well dishes and increasing concentrations of HS-173 were added just 
prior to time lapse imaging.  A) Representative images from 0 hrs and 72 hrs of each drug 
concentration. Images were taken every 2 hrs for 72 hrs. Green line represents wound edge, generated 
by Incucyte software. B) Quantification of wound confluence over 72 hrs for each treatment group. C) 
Final relative wound confluence of all treatment groups. Experiments were carried out in triplicate, 






Untreated H2 cells were unable to close the wound over the course of 72 hrs. Visually, 
the cells seemed to instead layer on top of each other on the outer edges instead of migrating 
inwards, to the point that making out individual cells was difficult (Fig. 4.7 A). Because of this 
extremely confluent monolayer, there was quite a noticeable amount of cell debris and round 
cells on the outer edges, although more towards the center of the well, single elongated H2 cell 
were apparent. Cells exposed to 0.05 µM had barely any qualitative differences compared to 
the untreated cells, and although 0.1 µM samples had a non-significant variability in wound 
closure (Fig. 4.7 B, C), the outer cells were much more granular and rounded. Exposure to the 
two highest doses resulted in both a significant difference in wound closure and morphology. 
Cells in the monolayer had barely any “typical” H2 morphology visible, as all cells were 
extremely rounded and granular.  



























































































Figure 4.7: Migration of H2 cells during exposure with varying concentrations of HS-173. Cells were 
seeded at 30 000 cells/well in 96-well dishes and increasing concentrations of HS-173 were added just prior 
to time lapse imaging. A) Representative images from 0 hrs and 72 hrs of each drug concentration. Images 
were taken every 2 hrs for 72 hrs. Green line represents wound edge, generated by Incucyte software. B) 
Quantification of wound confluence over 72 hrs for each treatment group. C) Final relative wound 
confluence of all treatment groups. Experiments were carried out in triplicate, n=6 per concentration. 






Untreated H3 cells fully closed the wound and phenotypically, untreated, 0.05 µM-
treated, and 0.1 µM-treated cells were very similar. H3 cells had a consistent confluency and 
morphology for both those that filled the wound and those on the outer frame (Fig. 4.8 A), 
although when quantified, 0.05 µM and 0.1 µM resulted in slightly slower wound closures (Fig. 
4.8 B). Cells treated with 0.3 µM had a significant drop in wound closure compared to the 
control as well as those treated with 0.5 µM (Fig. 4.8 C). H3 cells treated at 0.5 µM displayed 
a very different morphology to what was seen in untreated cells, which also reflects what was 
seen in Fig. 4.4.  
Figure 4.8: Migration of H3 cells during exposure with varying concentrations of HS-173. Cells were 
seeded at 30 000 cells/well in 96-well dishes and increasing concentrations of HS-173 were added just prior 
to time lapse imaging. A) Representative images from 0 hrs and 72 hrs of each drug concentration. Images 
were taken every 2 hrs for 72 hrs. Green line represents wound edge, generated by Incucyte software. B) 
Quantification of wound confluence over 72 hrs for each treatment group. C) Final relative wound 
confluence of all treatment groups. Experiments were carried out in triplicate, n=6 per concentration. 






Untreated H10 cells did not close the wound entirely after 72 hrs. The outer cell growth 
was extremely confluent (Fig. 4.6 A), however the migration of the cells into the wound only 
reached 80% of maximum. The cells after 72 hrs still had a very typical elongated fibroblast-
like shape. Even the cells treated with the lowest dose, 0.3 µM, the wound closure was visibly 
slower than the untreated control. It was difficult to see the base layer of cells, however similar 
to Fig. 4.5 there were many round cells compared to the untreated cells, although it was difficult 
to tell if these were floating. As the dosages increased, there was less of a tightly formed 
monolayer surrounding the wound and it was possible to see the more oblong shape of adhered 
cells. In Fig. 4.6 B, the untreated cells had a slow but semi-logarithmic growth curve, whereas 
all treated samples had a flat line with a very low slope. The final wound confluence (Fig. 4.6 
C) showed extremely significant reduction of wound closure at all concentrations.  
Figure 4.9: Migration of H10 cells during exposure with varying concentrations of HS-173. Cells were 
seeded at 30 000 cells/well in 96-well dishes and increasing concentrations of HS-173 were added just 
prior to time lapse imaging. A) Representative images from 0 hrs and 72 hrs of each drug concentration. 
Images were taken every 2 hrs for 72 hrs. Green line represents wound edge, generated by Incucyte 
software. B) Quantification of wound confluence over 72 hrs for each treatment group. C) Final relative 
wound confluence of all treatment groups. Experiments were carried out in triplicate, n=6 per 





4.3 HS-173 induces apoptosis in H1, H2, H3 and H10 cell lines 
 An apoptosis assay was performed to determine if HS-173 causes the melanoma 
metastases cell lines to undergo apoptosis, and possibly explain the morphological changes the 
cells underwent after exposure.  
 
The apoptosis profile of untreated H1 cells (Fig. 4.10) was a typical healthy cell culture 
with total apoptosis and necrosis below 10%. As HS-173 concentrations increased, the 
surviving cells decreased and there were much larger populations in the apoptotic quadrants, 
although there was not a large population of necrotic cells as the inhibitor concentration 
increased. The lowest concentration (0.1 µM) had no visual differences in apoptotic profile but 
starting at 0.3 µM the apoptosis in the population was clearly higher than untreated control.  
 
 H2 untreated cells (Fig. 4.11) also showed less than 10% of total apoptotic and necrotic 
cells. For the first two drug concentrations (0.05 µM, 0.1 µM) the apoptotic profile was not 
Figure 4.10: Flow cytometric analysis of apoptotic profile after treatment of H1 with increasing 
concentrations of HS-173. Dot plots are representative samples of H1 fluorescent profile after treatment for 
72 hrs of 0.1 µM, 0.3 µM, 0.5 µM and 1.0 µM of HS-173. FITC-Annexin V labels cells undergoing early 
apoptosis, and PI labels late apoptotic/necrotic cells. Experiments were performed in triplicate. 
Abbreviations:  Q1: necrotic cells, Q2: late apoptotic cells, Q3: early apoptotic cells, Q4: viable cells. 
Figure 4.11: Flow cytometric analysis of apoptotic profile after treatment of H2 with increasing 
concentrations of HS-173. Dot plots are representative samples of H2 fluorescent profile after treatment for 
72 hrs of 0.05 µM, 0.1 µM, 0.3 µM, and 0.5 µM of HS-173. FITC-Annexin V labels cells undergoing early 
apoptosis, and PI labels late apoptotic/necrotic cells. Experiments were performed in triplicate. 





entirely discernible from the untreated control, however at 0.3 µM there was a shift of the cell 
population into early and late apoptosis. Although 0.5 µM had much more apoptotic cells than 
the untreated control, there were no clear dense population in either Q2 or Q3. 
 
 
The H3 cells (Fig. 4.12) had a similar profile to the H2 cells. Treatments with 0.05 µM 
or 0.1 µM did not result in noticeably larger populations of apoptotic cells than those in the 
untreated control, but at 0.3 µM there was a shift of the population into both early and late 
apoptosis. The highest concentration at 0.5 µM however did show clear populations of both 
early and late apoptotic cells, while the majority of the population was still viable according to 
the density of the dot plot.   
 
All H10 samples (Fig. 4.13) with HS-173 pre-treatment had a visible difference in 
apoptotic profile compared to the control. While the lowest concentration, 0.3 µM, only showed 
Figure 4.12: Flow cytometric analysis of apoptotic profile after treatment of H3 with increasing 
concentrations of HS-173. Dot plots are representative samples of H3 fluorescent profile after treatment for 
72 hrs of 0.05 µM, 0.1 µM, 0.3 µM, and 0.5 µM of HS-173. FITC-Annexin V labels cells undergoing early 
apoptosis, and PI labels late apoptotic/necrotic cells. Experiments were performed in triplicate. 
Abbreviations:  Q1: necrotic cells, Q2: late apoptotic cells, Q3: early apoptotic cells, Q4: viable cells. 
Figure 4.13: Flow cytometric analysis of apoptotic profile after treatment of H10 with increasing 
concentrations of HS-173. Dot plots are representative samples of H10 fluorescent profile after treatment 
for 72 hrs of 0.3 µM, 0.5 µM, 1.0 µM and 1.5 µM of HS-173. FITC-Annexin V labels cells undergoing 
early apoptosis, and PI labels late apoptotic/necrotic cells. Experiments were performed in triplicate. 





marginal differences, there were distinct cell populations in both early and late apoptotic phases. 
While these populations did increase in number as the concentration increased, there was not a 
very large change between 1.0 µM and 1.5 µM despite the large change in concentration. 
Interestingly, despite the large amounts of apoptotic cells, there was not a marked increase in 
necrotic cells.  
 The decrease in cell viability, or increase in apoptosis, reflected the results seen in the 
scratch wound. The drug had a significant effect on cell function at the two highest doses across 
all cell lines (Fig. 4.14).  In H1 and H3, cell viability was decreased to around 60% at the highest 
dose, whereas in H2, 70% of cells survived the highest treatment of HS-173. H10 was extremely 
susceptible in all doses except 0.3 µM. Cells treated at 1.0 µM and 1.5 µM both had around 
40% of viable cells. Overall, the apoptosis was less than expected in H1 and H2 based on the 
IC50 results, but it should be noted that IC50 does not necessarily reflect the concentration at 
which 50% of cells are dead.   
4.4 HS-173 effects reduce activation of major proteins in PI3K 
pathway    
 
Western blotting was performed to assess the actual effect of HS-173 on key proteins in 
the PI3K pathway. Three different timepoints were used to visualize the inhibitory effects of 
the drug. Unfortunately, due to coronavirus restrictions, there was only time to perform the 72 
Figure 4.14: Quantification of apoptotic profile after treatment of all cell lines with increasing 
concentrations of HS-173. Percentage of viable, early apoptotic and late apoptotic/dead cells was calculated 
for H1, H2, H3 and H10 cell lines. Two-way ANOVA compared viable populations between each drug 





hrs timepoint for H3, and there was only time to perform one experiment per cell line. It is also 
important to note that H3 only had 20 µg of protein added, while optimized H1, H2 and H10 
had 30 µg.  
 
According to Fig. 4.15, the effect of HS-173 on H1 cells was mainly seen in the 
phosphorylation of Akt, across all three time points. Akt remained unchanged in both treated 
and control, however there was a very large decrease in the phosphorylated protein even as 
early as 24 hrs. After 72 hrs, there were several non-specific bands detected. HS-173 did not 
appear to have a large effect on phosphorylation of mTOR, although there was a slight decrease 
Figure 4.15: Expression of PI3K pathway proteins in H1 cells after treatment with 1.0 µM HS-173 for 24 





in detection after 48 hrs in the treated sample.  PI3K also had relatively consistent expression 
PI3Kα, but similarly to mTOR, expression was slightly lower in the 48 hrs time point.  
 
As shown in Fig. 4.16, the major effect of HS-173 on H2 cells could be detected in the 
phosphorylation of Akt. The effect seemed the most prevalent at the 72 hrs timepoint, where 
there was a clear decrease in the amount of p-Akt in the treated cells compared to untreated 
cells, while the unphosphorylated Akt did not change. Again similar to H1, there was some 
non-specific banding in the earlier timepoints in both control and treated samples. Both 
unphosphorylated and phosphorylated mTOR expression was consistent across treatments and 
samples. PI3Kα also showed some reduced expression in the 72 hrs timepoint, consistent with 
the p-Akt results.  
 
Unfortunately  due to coronavirus-related time constraints, Fig. 4.17 only showed the 
72 hrs time point of H3 proteins instead of the dynamics over three days. However, it was still 
clear that Akt phosphorylation was reduced even after 72 hrs. There is also possibly a very 
small decrease in p-mTOR and PI3K although it is extremely small and difficult to confirm.  
Figure 4.16: Expression of PI3K pathway proteins in H2 cells after treatment with either 0.5 µM of HS-173 
for 24 hrs, 48 hrs and 72 hrs. N=1.  
 
Figure 4.17: Expression of PI3K pathway proteins in H3 cells after treatment with either 0.5 µM of HS-173 







  H10 cells had an immediate reduction in Akt phosphorylation after 24 hrs, although the 
expression slowly recovered over the next two time points (Fig. 4.18).  There were no major 
changes in the other protein level expressions, although it seemed that phosphorylation of 
mTOR was slightly increased at 24 hrs and leveled off as time continued, and PI3Kα had a 
slight decrease in 24 hrs and 48 hrs, but again recovered after 72 hrs.  
  
Figure 4.18: Expression of PI3K pathway proteins in H10 cells after treatment with either 1.0 µM of HS-173 






 Brain metastases are an extremely fatal and common outcome for patients with 
advanced melanoma. Around 70% of melanoma patients develop brain metastasis79, and the 
survival is measured in a few months after diagnosis, even with the most extensive treatment80. 
Current treatments are not effective, among others due to poor drug penetration through the 
blood-brain barrier, these tumours are inherently radioresistant and they develop treatment 
resistance after a few months103. Thus, advancements in treatments such as targeted therapeutics 
are urgently required.  
 In this thesis, we show that the selective PI3Kα inhibitor HS-173 effectively inhibits 
growth of melanoma brain metastasis cell lines in vitro. Due to its small molecular size (422.46 
Da) and hydrophobicity, HS-173 could be a promising candidate for subsequent animal studies, 
with the aim of bringing the drug into the clinic as an adjuvant treatment.  
5.1 HS-173 effectively decreased cell viability      
HS-173 inhibited cell viability in a dose-dependent manner in all four melanoma brain 
metastasis cell lines, even at doses as low as around 0.1 µM (Fig. 4.1). The viability curves 
were much steeper for the H2 and the H3 cells than the two other cell lines, indicating that 
incremental changes in concentration would have a larger inhibitory effect, which could explain 
the disparity in the IC50 doses (Fig. 4.2). The mean IC50 dose taking all cell lines into account 
was around 0.5 µM, and the lowest IC50 dose found was 0.15 µM for the H2 cell line, which is 
low compared to other studies139,141,148.  
Our monolayer viability results are in line with previous studies, which have shown the 
effectiveness of HS-173 (similar IC50 doses as ours) on other cancer cell lines, including 
squamous cell carcinoma, breast cancer, liver cancer and pancreatic cancer. Rumman and 
colleagues used an MTT assay on monolayers to show that pancreatic cancer cell lines had IC50 
doses of around 1 µM141. 
Lee and colleagues tested the effects of HS-173 on liver cancer (HepG2, Huh7, Hep3B) 
and breast cancer (SkBr3, T47D, MCF-7) cell lines using an MTT assay. Both liver cancer and 
breast cancer had high rates of PI3Kα activating mutations, and the most sensitive cell line was 
HepG2 with an IC50 dose of only 0.045 µM, while the T47D showed lowest sensitivity at 0.4 
µM139. It has been previously reported that HepG2 is a susceptible cell line to PI3Kα inhibition, 





It has also been shown that in pan-PI3K-resistant squamous cell carcinoma with PIK3CA 
activating mutations, HS-173 had a range of IC50 doses from under 1 µM to 25 µM
148.  
Interestingly, although none of the cell lines tested in this thesis had PIK3CA activating 
mutations151, their sensitivity to PI3Kα inhibition was still comparable to cancer cells harboring 
such mutations151. The cell lines used in this work have also previously been evaluated with the 
pan-PI3K inhibitor buparlisib, using the same protocol as in this thesis121. H1 and H2 cells were 
found to have around 2- to 8-fold lower IC50 doses using HS-173, compared to buparlisib 
treatment. The H3 cell line was found to be relatively resistant to buparlisib with an IC50 of 
around 20 µM, which is more than 10-fold higher than the IC50 of H3 to HS-173 (0.15 µM). On 
the contrary, H10 exhibited a higher IC50 to HS-173 when compared to buparlisib (1.0 µM 
compared to 0.43 µM). These results are corroborated by a high throughput screening study by 
Ryoo and colleagues aiming at investigating compounds suppressing miR-21 expression in the 
MDA-MB-231 breast cancer cell line. HS-173 was found to be a promising candidate, as the 
drug suppressed miR-21 expression more effectively compared to the pan PI3K inhibitors 
Wortmannin and LY294002, along with lower IC50 doses
152.   
A possible explanation for the observed differences in IC50 doses may be that a larger 
amount of drug may be required in order to saturate and inhibit all PI3K isoforms, whereas the 
specificity of HS-173 means a lower concentration to fully inhibit the protein of interest. This 
is the reasoning behind introducing isoform-specific inhibitors in the clinic over pan-inhibitors, 
to reduce maximal doses and toxicity153. Additionally, pan-PI3K inhibitors may illicit a larger 
cellular response because they inhibit all forms of PI3K, which may trigger tumour cells to 
initiate resistance mechanisms more quickly.   
These findings indicate that even without the activating PIK3CA mutation, HS-173 
acted as an effective inhibitor of cell viability in all four melanoma cell lines. It functions as a 
more consistent growth inhibitor than the pan-PI3K inhibitor buparlisib in the same cells, 
decreasing cell growth in all cell lines including H3, a cell line which is resistant to buparlisib.  
In order to substantiate the monolayer viability results, our initial plan was to perform 
viability studies in a 3D assay, by embedding the cells into soft agar. This is an assay which 
more closely mimics the environment in vivo, as the cells would be restricted by the agar and 
form spheroids, thus forming similar tumour structures as seen in patients154. Then, the idea 
was to treat the cells with similar dosages as used for the monolayer viability studies, over a 





no time to carry on these experiments. In a previous study the PARP inhibitor PJ34 was found 
to inhibit the growth of H1 and H3 spheroids in a similar manner as seen in monolayer 
experiments155. Thus, it is likely that we would have observed similar, inhibitory effects using 
HS-173. We can of course not say whether treatment of 3D tumour structures with HS-173 
would be as effective as monolayer treatment. However, it is worth mentioning that in previous 
studies treating H1 cells with memantine and thiostrepton, larger inhibitory effects were seen 
for both drugs on spheroids, compared to monolayers156. In contradiction, in Aasen and 
colleague’s paper where H1, H2, H3 and H10 were tested with pan-PI3K inhibitor buparlisib, 
monotherapies were less effective in a 3D format121. This is a common result seen in 2D vs 3D 
culture systems, as in colonies cells tend to have more resistance to drug treatments because 
they more reflect the in vivo tumour environment.     
5.2 HS-173 induces morphology changes in brain metastasis cell lines  
In order to investigate potential morphological changes in cells over the course of 
treatment, light microscopy images were taken of each cell line after 72 hrs of treatment with 
increasing doses of HS-173. While each cell line had minor changes in morphological 
differences, the overall effect was similar. HS-173 induced a population of unattached, rounded 
cells as doses increased, and those that remained attached had reduced filopodia and spindles.  
 Rumman and colleagues found similar results on pancreatic cancer cell lines. In this 
study, migration was promoted through TGF-β exposure, and morphological changes upon 
treatment with HS-173 were assessed. TGF-β induced a mesenchymal phenotype in untreated 
cells, however those treated with 5 µM HS-173 had a more “cuboidal” shape with less 
filopodia141. Similar morphological changes were also reported during treatment with buparlisib 
by Aasen and colleagues121.  
The most likely explanation of the morphological change is by initiation of apoptosis in 
the cells. Apoptosis begins with a “rounding up” of cells, followed by blebbing of the surface 
membranes, and finally formation of fragmented apoptotic bodies157. This is especially notable 
in the H2 and H3 cell lines, where cell debris was present at the higher doses of HS-173 (Fig. 
4.3, 4.4). H1 and H10 (Fig. 4.2, 4.5) cells did have smaller pieces of cell debris, but there were 
larger more rounded cells with no blebbing membranes. While this could indicate the initial 
stages of apoptosis, there is evidence that PI3K inhibition also may cause this type of 
morphology independent of apoptosis. In Aasen and colleague’s paper, melanoma cells treated 





cells treated with trametinib had an elongated morphology. Both these treated cells were found 
to be undergoing similar amounts of apoptosis, indicating that this morphology could be related 
specifically to PI3K pathway inhibition as well as apoptosis121.  
In a study by Wallin and colleagues, an invasive cell line was created from normal 
MCF10A, a non-tumourigenic human breast epithelial cell line, by knocking in an activating 
mutation in PIK3CA. It was found that the invasive cells developed a spindle-like, fibroblast 
morphology, and that this morphology was reversible when treated with PI3K inhibitors, both 
pan and isoform-specific158. Ryoo and colleagues also found that when their breast cancer cells 
were treated with HS-173, the cells exhibited a round shape. They speculated this could be due 
to the reversal of EMT transition through the reduction of miR-21 expression and upregulation 
of PTEN152.  
Overall, HS-173 induced morphological changes most likely attributed to apoptosis. 
However, the observed round phenotype has been seen in other studies evaluating the effect on 
the PI3K pathway in cancer and could implicate a cellular response other than apoptosis, related 
to metastasis and EMT transition152,158.  Time restriction did not allow us to pursue this matter 
any further. 
5.3 HS-173 reduces cell growth and migration in melanoma metastasis 
cell lines  
The scratch wound assay showed that HS-173 reduced the capacity of the cells to close 
the wounds in a dose-dependent manner (Fig. 4.6-4.9). For all cell lines, the two highest doses 
effectively reduced cell migration. However, the H2 cell line where untreated controls did not 
have the ability to close the wound, seemed to be less affected by the anti-migrational effect of 
the drug. 
Out of the four publications in which cells were treated with HS-173 and wound-healing 
assays were performed139,141,152,159, all found that HS-173 reduced cell migration. In a study by 
Lee and colleagues, HUVEC cells were plated and migration was induced by the addition of 
VEGF, a growth factor often implicated in cancer metastases139. HS-173 was shown to reduce 
the migration of cells into the wound after 18 hrs. It should be noted that the doses used were 
much higher (10 µM and 50 µM) than those used in the 3 other papers, and also in this thesis. 
This increased dosage required to illicit a response in HUVECs, a non-tumourigenic cell line, 
is also an indication that HS-173 has a ‘therapeutic window’ in which tumour cells are affected 





Rumman and colleagues performed a wound healing assay with pancreatic cancer lines 
and induced EMT-related migration by supplementing the media with TGF-β. They discovered 
that TGF-β-only treated cells migrated much faster than the untreated control, but those treated 
with both TGF-β and HS-173 reduced wound migration in a dose-dependent manner141. Ryoo 
and colleagues observed a more than 20% decrease in wound healing in their HS-173-treated 
breast cancer cell line152.  In a study aiming to investigate the Wnt-5a activated migration of 
osteosarcoma cells, it was found that the cell lines exhibited a significantly reduced capacity of 
wound healing when treated with only 1 nM of HS-173. The authors concluded that PI3K acted 
as a downstream pathway from Wnt-5a to induce osteosarcoma migration and invasiveness159.  
Our results on cell migration may be explained by the following. We have already 
shown that viability decreases at the doses of HS-173 used in this work, and inhibited cell 
growth and apoptosis would prevent migration (Fig. 4.1, Table 4.1). On a molecular level, it 
has also been demonstrated that Wnt5a overexpression in melanoma cell lines increases 
melanoma invasion, and expression levels of Wnt5a in human melanoma biopsies correlates 
with increased tumour grade160. Wnt5a signaling has been related to increased p-Akt levels, and 
acts as a positive effector of  migration in melanoma161. We have shown here that p-Akt is 
reduced upon treatment of HS-173 in our cells (to be explained further in Section 5.5), and this 
could explain the reduced migration we see across all cell lines. If this is the case, not only 
would HS-173 have the capacity to stop tumour growth, but also possibly inhibit further 
dissemination of metastases. Furthermore, as previously discussed in Section 5.2, if the 
phenotype change after HS-173 treatment is due to reversal of EMT, there would be a reduction 
in migration compared to the control, as cells typically become more mobile after undergoing 
EMT.  
  
5.4 HS-173 induces apoptosis in melanoma metastasis cell lines 
 In order to find out if the morphological changes could be attributed to apoptosis, we 
performed an annexin V/PI assay using flow cytometry. Apoptotic cell populations were 
confirmed to increase in a dose-dependent manner, (Fig. 4.11, 4.12). H2 had a viability of 
roughly 70%, and H3 around 60% at doses 2-5 times higher than the IC50 which reflects 
numbers seen in the literature. H1 and H10 cells (Fig. 4.10, 4.13) had a comparatively larger 





viable cells to around 40% at 1.0 µM, and a similar amount at 1.5 µM, while H1 had around 
50% viable cells at 1.0 µM (Fig. 4.14).  
 Overall, apoptotic numbers in H2 and H3 cells reflect those found in the literature, while 
H1 and H10 cells actually show more apoptosis after treatment than in most studies. Lee and 
colleagues found that upon treatment with 1.0 µM HS-173, Hep3B and SkBr3 cells both had 
significant increases in cells arrested in G2/M phase, from 10-20% in control cells to 50-70% 
in treated cells. Treated cells were also around 30-40% positive in TUNEL assays compared 
to <10% in the controls139. These apoptotic numbers reflect what we found in some of our cell 
lines, although it should be noted these experiments were run with a 24 hrs time point. In the 
same study, a JC-1 assay quantifying mitochondrial stress found 20-30% cells undergoing 
apoptosis compared to 3-7% in the controls139.  
 Yun and colleagues utilized TUNEL staining to quantify apoptosis in HS-173 treated 
Panc-1 pancreatic cancer cells, also using 1 µM for 24 hrs. Again, around 30-40% of cells were 
undergoing apoptosis, compared to the control at around 20%. HS-173 treatment also caused a 
very minor increase in G2/M arrest, although there were no statistics performed
162.  
Although our results are corroborated by the literature, we were hoping to further 
investigate the induction of apoptosis in our cells by HS-173. Most studies showed apoptosis at 
a 24 hrs time point, and with our 72 hrs time point, the cells may have been undergoing the 
entire apoptotic process and been completely destroyed. In the ungated samples with the highest 
concentration of drugs, the amount of debris gated out was higher (>10%) than in the control 
(data not shown). In the images taken of each condition, H2 cells (Fig. 4.2) and H3 cells (Fig. 
4.4) had a large amount of cell debris, especially in the 0.5 µM sample. In addition, in the 
preparation of samples the cells were spun down at 400 x g and filtered. Larger apoptotic bodies 
can be pelleted at 400 x g but in experiments for isolating apoptotic bodies, samples are typically 
spun at 1000 to 4000 x g which would mean we are losing them in the sample preparation 
process163. Even if they were to be included however, debris cannot be counted in flow 
cytometry as each ‘event’ is representative of a single cell, and if debris is included results can 
be skewed.  
 Initially, we planned to test this hypothesis by performing the experiments again at 24 
hrs timepoint instead of 72 hrs, so we could see more immediate effects of HS-173 on each cell 





cytometry as well. Unfortunately, due to the coronavirus shut-down these experiments could 
not be performed.  
5.5 HS-173 downregulates activation of key proteins in the PI3K 
pathway 
 In all our cell lines, the main effect of HS-173 treatment was a reduction in Akt 
phosphorylation at Ser473. The timeline of effects varied between cell lines, with H1 having the 
main effect at 24 hrs (Fig. 4.15) and 48 hrs and H2 at 72 hrs (Fig. 4.16). Unfortunately, due to 
time constraints, it was not possible to get all three timepoints for the H3 cells, but the effect of 
HS-173 was still visible after 72 hrs (Fig. 4.17).  In Fig. 4.18, H10 had an immediate response 
to HS-173, and p-Akt expression was lowest at 24 hrs and recovered across the next two days.  
 There are several studies presenting the same effect of HS-173 on p-Akt 
expression139,142,143,148,162,164. Jung and colleagues tested HS-173 in overactive fibroblast plaque 
tissue from patients with Peyronie’s disease. At a dose of 5 µM administered for 24 hrs, the 
cells had almost no expression of p-Akt, compared to the control samples164. Lee and 
collaborators studied the Akt phosphorylation sites Thre308 and Ser473 in liver cancer and breast 
cancer cell lines after 24 hrs of treatment with 0.1 µM, 0.5 µM and 1.0 µM of HS-173. Both 
cell lines had reduced p-Akt expression levels after being exposed to 0.5 µM, most notably at 
the Ser473 site139. Michmerhuizen and colleagues used a dose of 5 µM HS-1173 on six squamous 
cell carcinoma cell lines and in all of them, an inhibitory effect was shown in Akt 
phosphorylation148. 
 Miapaca-2 and PANC-1 cells were studied by Yun and colleagues in a single treatment 
experiment, where they determined that 1 µM of HS-173 was sufficient to almost completely 
inhibit p-Akt expression162. These same cells were utilized to evaluate the ability for HS-173 to 
inhibit p-Akt in experiments where p-Akt was previously upregulated by using radiation. Park 
and co-workers studied the effect of HS-173 on irradiated pancreatic cancer cell lines (Miapaca-
2 and PANC-1). Cells that were irradiated with 10 Gy had a significant increase in p-Akt levels, 
and HS-173 was able to reduce the expression of p-Akt below the control sample levels and 10 
Gy irradiated samples in doses from 1 - 5 µM of HS-173142.   
Overall, it seemed as though phosphorylation of mTOR was not largely affected by HS-
173 at the doses used in this work. Some minor changes were seen, particularly in H1 cells at 
48 hrs (Fig. 4.15), and H2 cells at 72 hrs. Since these experiments were only carried through 





3 independent experiments.  In the literature, mTOR activation is found to be less affected by 
HS-173 than Akt activation, although activation inhibition could be seen in higher doses, and 
in shorter time points139,164. 
 Jung and colleagues also found that mTOR phosphorylation was reduced by HS-173, 
but not to the degree in which p-Akt was affected and requiring almost 4 times the dose (20 
µM) to cause a large decrease in expression. It is worth noting that they also performed 
immunocytochemistry (ICC) on the cells after only a 6 hrs exposure, and p-mTOR had a much 
larger decrease in expression at this timepoint at only 1 µM, suggesting that the activation of 
mTOR is affected, but recovers very quickly164.  Lee and colleagues also found very similar 
results in their liver and breast cancer cell lines, that inhibition of mTOR phosphorylation 
required a higher dose than in p-Akt, and that in ICC with a short exposure time (2 hrs), p-
mTOR expression was barely visible139.  
It is possible that mTOR recovers more quickly as it is further downstream from the 
protein being inhibited, resulting in higher probability for compensation mechanisms from 
other effectors. Additionally, mTOR protein forms two major complexes in the cell (mTORC1 
and mTORC2), one downstream from Akt and one upstream. A larger amount of inhibition 
may be required before a significant decrease can be detected through western blotting. 
Although Akt does have some PI3K-independent methods of activation, the major mechanism 
occurs directly from PI3K catalysis of second messenger PIP3. A known mechanism in cancer, 
found in melanoma specifically, for mTOR reactivation in response to PI3K pathway inhibition 
is downregulation of mTOR inhibitor TSC2, which has been proven to increase the activation 
of mTOR. TSC2 is inactivated by phosphorylation, and the kinases involved have been 
documented to play a role in PI3K inhibitor resistance165.  
Similar to p-mTOR, PI3Kα had minor changes in the treated samples versus the control. 
In all cell lines, at least one time point showed a slight decrease in PI3Kα, H1 (Fig. 4.15) at 48 
hrs, H2 (Fig. 4.16) at 72 hrs, H3 (Fig. 4.17) at 72 hrs, and H10 (Fig. 4.18) at 24 and 48 hrs.  
 No previous studies have assessed the effects of PI3Kα expression after HS-173 
treatment. Thus, it is not possible to relate our findings to any published work with isoform-
specific inhibition, however there are some publications evaluating pan-PI3K inhibition and 
PI3K expression. Aasen and colleagues studied buparlisib and trametinib on metastatic 
melanoma cell lines, and found that PI3K was reduced in the presence of buparlisib, equally as 





effect of two PI3K inhibitors, wortmannin and LY294002 in a laryngeal carcinoma xenograft 
mouse model. During single treatments with each inhibitor, tumour cells were found to have a 
significantly reduced amount of PI3K expression compared to the control166.  
 In summary, HS-173 downregulated the expression levels of p-Akt, a major regulator 
in the PI3K pathway. Additionally, there were some indications that activation of p-mTOR and 
the expression of PI3Kα was altered after HS-173 treatment, although not to the degree of p-
Akt. Based on previous research, it is reasonable that with PI3Kα inhibition there would be 
reduction in its own expression. The PI3K pathway in melanoma is thought to have self-
promoting feedback loops and inhibiting the pathway could alter expression of the protein 
itself167. Unfortunately, due to time constraints we could not perform triplicate experiments 
with quantifications to reliably verify these findings.  
5.6 Experimental Limitations and Considerations 
 There are several things that should be taken into consideration in terms of HS-173 as a 
possible therapeutic agent. A major issue with targeted therapies is acquired resistance to the 
drug being used. Melanoma has several mechanisms to adjust signaling in response to pathway 
inhibition as previously discussed, and therefore monotherapies are rarely very effective in 
patients for very long. In the case of HS-173, the target of interest is isoform-specific and 
therefore allows the possibility for cells of isoform switching. However, combined therapy is 
likely required to inhibit the upregulated PI3K pathway at several levels, in addition to other 
pathways that could be activated in response to treatment (i.e. MAPK). In this case, the HS-173 
specificity and low effective doses could be beneficial. 
 HS-173 has been shown in several studies to work in combination with other inhibitors 
in a synergistic fashion. HS-173 enhanced the efficacy and penetration of doxorubicin into MIA 
PaCa-2 and B16 tumours in vivo140 and displayed potential synergy with gefitinib (EGFR 
inhibitor) in advanced stage head and neck squamous cell carcinoma143. A synergistic 
anticancer effect was also induced by HS-173 in combination with sorafenib (multi-kinase 
inhibitor in MAPK pathway) in pancreatic cells. Although these results cannot definitively 
predict that HS-173 will always work in a synergistic function when combined with other drugs, 
it is promising that it does so with inhibitors of the MAPK pathway.  
It has been shown that in BRAF-mutant melanoma, PI3K pathway inhibitors can be 
effective in tumours without major PI3K pathway mutations136. Nevertheless, determining the 





the future. Although it is impossible to say which specific mutations are relevant in this thesis 
without further experimentation, a previous mutational analysis was considered in order to 
begin investigating the possible explanation. 
 There are several mutations previously found in melanoma that can activate the PI3K 
pathway. Mutations in RTKs, which activate PI3K at the very beginning of the pathway, can 
increase the activity of the pathway. RTK mutations have been found in up to 49% of cutaneous 
melanomas, and mutations directly within the PI3K pathway have been found in 56%40. H1 and 
H10 both have mutations in the FGFR2 gene, and H10 has a mutation in both EGFR and 
PDGFRB genes, all of which are RTKs that can activate the PI3K pathway151. TSC1, an 
inhibitory effector to mTOR, is also mutated in H1. Inactivating mutations in TSC1, like PTEN, 
can lead to PI3K pathway activation. NRAS, which codes for the NRAS protein in the MAPK 
pathway, has also been found to stimulate PI3Kα activation151. Additionally, it has been 
speculated that the PI3K pathway plays an important role in mediating BRAF inhibitor 
resistance, suggesting that melanoma tumours have the ability to upregulate the PI3K pathway 
upon induced resistance to MAPK pathway targeted treatments although the mechanisms 
behind this requires more investigation168.  
A major obstacle in treatment of melanoma brain metastases is to deliver drugs across 
the blood brain barrier. There have been no studies so far showing that HS-173 can penetrate 
through the brain microvasculature, although the molecular characteristics are promising. It is 
a small molecule at only 422.46 Da, in addition to being lipid soluble and therefore has the 
potential to be able to cross the BBB. Furthermore, the BBB tends to lose the integrity in the 
presence of a tumour, additionally facilitating the possibility of HS-173 to be utilized to treat 
brain metastases169.  
In this thesis, we studied the in vitro effects of HS-173. The drug has also shown 
promising effects in vivo. In a xenograft model with PANC-1 and Miapaca-2 pancreatic cancer 
cell lines, HS-173 was found to reduce tumour growth and sensitize the tumours to radiotherapy 
at a dose of 10 mg/kg, 5 times/week for four weeks142. Rumman and colleagues utilized three 
pancreatic mouse cancer models: a xenograft model, an orthotopic model and a metastasis 
model to liver, lung and lymph nodes.  In xenograft and orthotopic models, mice were treated 
with 10 mg/kg. Significant reduction in tumour sizes were observed, while no major changes 
in body weight and no adverse effects were noted141. The metastatic model was treated with 
either 10 mg/kg or 30 mg/kg three times a week for 25 days and resulted in significant 





Moving forward it is important to evaluate HS-173 in our own in vivo brain metastasis 
mouse models, to be discussed further in Future Aspects.  
Conclusion  
Overall, the results of this study support previous literature showing anti-cancer effects 
of HS-173. The drug inhibited cell viability and induced apoptosis in a dose-dependent manner. 
All cell lines showed rounded morphological changes after treatment, which may be attributed 
to apoptosis, and this could also indicate a reduction in Akt dependent-EMT potential.  
Proliferation and migration were reduced in the presence of HS-173, as shown by a wound-
healing assay. Western blots demonstrated that the PI3K signaling pathway was affected, with 
major reductions in Akt protein expression levels, and minor changes in expression levels of 
mTOR and PI3Kα.   
In conclusion, we demonstrate for the first time that the PI3Kα inhibitor HS-173 
effectively inhibits the growth of human melanoma brain metastasis cell lines in vitro. The 
promising results should be followed up with further studies, to determine its potential 
applicability in the clinic. 
Future Aspects  
To establish the use of HS-173 as a therapeutic option in the treatment of melanoma 
brain metastasis, several additional experiments need to be performed. 
HS-173 was effective in monolayer cultures, however these assays do not reflect the 
three-dimensional (3D) growth seen clinically. Thus; 3D in vitro assays such as the soft agar 
assay should be performed to establish that the drug also is effective in a clinically more relevant 
situation. We started on these experiments, but they are considerably more time-consuming 
than monolayer assays, and we had to discard the culture plates when the lab was closed in 
March. 
Due to time constraints, we were not able to verify the western blots in triplicate 
experiments, so this should be repeated on the signaling proteins studied in this thesis. Also, 
the drug doses should be increased, to establish that the drug inhibits protein levels such as p-
mTOR and PI3Ka, which were only modestly affected in this study. Previous literature has 





 The effects of HS-173 on caspases could also be evaluated with western blotting to 
corroborate the apoptosis data gathered from flow cytometry.  
Further, the effects on signaling proteins in the PI3K signaling pathway, such as BAD, 
CREB or FOXO should be evaluated by western blots. Also, potential crosstalk between the 
PI3K and the MAPK signaling pathways could be elucidated by blotting expression levels of 
MAPK proteins after drug exposure. Expression of E-cadherin and N-cadherin could also be 
investigated to elucidate if the morphology change of the cells is related to EMT reversal.   
We show that HS-173 induces apoptosis to a certain degree. In this respect, it may well 
be that drug treatment also induces for instance cell cycle arrest, which could easily be studied 
by flow cytometry. Time limitations did not allow us to follow up on this. 
Prior to moving into preclinical experiments, a therapeutic window for the drug has to 
be established. Thus, HS-173 should also be tested on healthy, non-tumourigenic cells such as 
brain astrocytes and endothelial cells to confirm that HS-173 will not induce cell death at the 
same doses as for the tumour cells. There is already an indication that non-tumourigenic cell 
lines (HUVECS) are less sensitive to HS-173, as discussed in Section 5.3.  
In vivo, the ability of HS-173 to penetrate an intact blood-brain barrier should be firmly 
established. This can be done by radiolabeling the drug with 11C, and then performing dynamic 
PET studies in non-tumour bearing animals. This is a feasible project, since the group has 
already established collaborations with Radiochemists at the PET Center (Haukeland 
University Hospital) and Medical Chemists at the Department of Chemistry, UiB.  
Next, animal treatment studies should be performed, using our well-established 
animal/tumour models. Human melanoma brain metastasis cells are injected intracardially into 
nod/scid mice, and brain metastasis development are monitored by MRI and PET/CT. Clinically 
relevant doses of HS-173 should be administered to the mice, and effects on tumour burden and 
animal survival should be recorded. Alpelisib, a PI3Kα inhibitor that has been shown not to 
cross the BBB, has been used in mouse models in doses of 12.5, 25 or 50 mg/kg, which could 
be used as a starting point for dose selection for effective treatment with HS-173170. Further, 
the pan-PI3K inhibitor buparlisib has previously been administered to mice at a dose of 50 
mg/kg, and based on our discussion of in vitro doses necessary for tumour cell inhibition 






Also, subsequent histology and immunohistochemistry would reveal changes in tumour 
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